Haemonetics layoffs, on the record
Every job cut, severance charge and restructuring Haemonetics reported in its annual reports, 2024 to 2026, quoted from the filings. Headcount went from 3,657 to 3,009 persons.
Headcount, as reported
| Annual report | Employees | As of |
|---|---|---|
| 10-K for 2024 | 3,657 | March 30, 2024 |
| 10-K for 2025 | 3,023 | March 29, 2025 |
| 10-K for 2026 | 3,009 persons | As of March 28, 2026 |
Job cuts, severance and restructuring
Our summaryCompany operates the Operational Excellence Program, expecting aggregate charges of $85 million to $95 million, mostly cash outlays including severance and other employee costs, substantially completed by end of fiscal 2025.
Word for word“We estimate that we will incur aggregate charges between $85 million and $95 million in connection with the Operational Excellence Program.” 10-K for 2024
Our summaryIn November 2023 the company announced plans to end of life the ClotPro analyzer system and certain Blood Center Whole Blood products, including closing related manufacturing operations and certain other facilities.
Word for word“In November 2023, the C ompany announced its plans to end of life the ClotPro analyzer system within the Hospital business unit and certain products within the Blood Center business unit, primarily in Whole Blood, including the associated manufacturing operations and closure of certain other facilities.” 10-K for 2024
Our summaryCompany reports a restructuring liability that is substantially all employee severance and other employee costs, payable within the next twelve months.
Word for word“As of March 30, 2024, the Company had a restructuring liability of $ 11.8 million, all of which is payable within the next twelve months.” 10-K for 2024
Our summaryBoard approved a new company-wide market and regional alignment restructuring initiative, with management delegated to set specific actions.
Word for word“During the first quarter of fiscal 2026, our Board of Directors approved a new market and regional alignment initiative, a company-wide restructuring initiative designed to improve operational performance and reduce costs by directing the Company's resources toward the markets and geographies that offer the greatest growth and portfolio advancement opportunities, and delegated authority to the Company's management to determine the details of the specific actions that will comprise the initiative.” 10-K for 2025
Our summaryExpected charges for the market and regional alignment initiative: about half for severance and employee costs, the rest for other exit costs, continuing through fiscal 2027.
Word for word“We expect to incur aggregate restructuring and restructuring-related charges of approximately $20 million associated with this initiative, approximately half of which we expect will consist of severance and other employee costs and the remainder of which will consist of other exit costs, primarily related to third party arrangements.” 10-K for 2025
Our summaryIncurred restructuring costs for the first action under the market and regional alignment initiative, approved by the Board in January 2025.
Word for word“During the fourth quarter of fiscal 2025, we incurred $0.6 million of restructuring related costs related to the first action under this initiative, which were approved by our Board of Directors in January 2025.” 10-K for 2025
Our summaryThe company incurred restructuring and related costs under its ongoing market and regional alignment initiative, a company-wide restructuring effort to cut costs and focus resources on the best growth markets.
Word for word“During fiscal 2026, we incurred restructuring and restructuring related costs of $5.1 million under this initiative .” 10-K for 2026
Our summaryThe Board approved the market and regional alignment initiative, a company-wide restructuring, and left management to decide the specific actions.
Word for word“During the first quarter of fiscal 2026, our Board of Directors approved our ongoing market and regional alignment initiative, a company-wide restructuring initiative designed to improve operational performance and reduce costs by directing the Company’s resources toward the markets and geographies that offer the greatest growth and portfolio advancement opportunities, and delegated authority to the Company's management to determine the details of the specific actions that will comprise the initiative.” 10-K for 2026
| Fiscal year ended | Restructuring charges | Restructuring costs incurred | Cash paid for restructuring |
|---|---|---|---|
| 2017-04-01 | $21.8 million | — | $22.3 million |
| 2018-03-31 | $30.5 million | $30.5 million | $8.3 million |
| 2019-03-30 | $395,000 | $395,000 | $21.4 million |
| 2020-03-28 | $3.6 million | $3.6 million | $8.3 million |
| 2021-04-03 | $1.4 million | $1.4 million | $3.1 million |
| 2022-04-02 | $4.2 million | — | $2.4 million |
| 2023-04-01 | $657,000 | — | $1.3 million |
| 2024-03-30 | $14.1 million | — | $4.4 million |
| 2025-03-29 | $13.9 million | — | $14.1 million |
| 2026-03-28 | $3.1 million | — | $4.8 million |
Haemonetics filed 3 restructuring notices (Form 8-K, Item 2.05) since 2016. This page shows what the company reported to the SEC, not news reports or state layoff notices.
Read from Haemonetics’s annual reports (10-K for 2026, 10-K for 2025, 10-K for 2024) and the financial data it files with the SEC, as of 2026-05-20. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.